title: Dietary and enteral interventions for Crohn's disease.
abstract: It is now widely acknowledged that the intestinal bacterial flora together with genetic predisposing factors significantly contribute to the immunopathogenesis of inflammatory bowel disease (IBD) as reflected by mucosal immune dysregulation. Recently, there has been an increased interest in nutraceutical therapies, including probiotics, prebiotics and synbiotics. Other dietary interventions with low carbohydrate diet, omega-3 polyunsaturated fatty acids and glutamine have been attempted to downregulate the gut inflammatory response and thereby alleviate gastrointestinal symptoms. Enteral nutrition has been widely used as induction and maintenance therapies in the management of Crohn's disease (CD). In this review, a critical assessment of the results of clinical trial outcomes and meta-analyses was conducted to evaluate the efficacy of dietary and enteral interventions for CD.
authors.affiliation: Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan. Electronic address: nao-taka@sannet.ne.jp.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yamamoto
authors.affiliation: Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shimoyama
authors.affiliation: Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan.
authors.forename: Moeko
authors.initials: M
authors.lastname: Kuriyama
mesh_terms: D003424:Crohn Disease / Q000178:diet therapy* / Q000188:drug therapy; D004032:Diet; D004750:Enteral Nutrition; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D006801:Humans; D056692:Prebiotics; D019936:Probiotics / Q000627:therapeutic use
chemical_list: D015525:Fatty Acids, Omega-3; D056692:Prebiotics